Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shigeki Ito

Showing results (141-150 of 142) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 142 results.
European Journal of Haematology|September 13, 2017
Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patientsKazunori Murai, Kohei Yamaguchi, Shigeki Ito, et al.
Blood Cancer Journal|October 6, 2025
Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)Jin Seok Kim, Yang Song, Wei-Ying Jen, et al.
Pageof 15

Showing results (141-150 of 142) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 142 results.
European Journal of Haematology|September 13, 2017
Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patientsKazunori Murai, Kohei Yamaguchi, Shigeki Ito, et al.
Blood Cancer Journal|October 6, 2025
Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)Jin Seok Kim, Yang Song, Wei-Ying Jen, et al.
Pageof 15